Oral Rigosertib for Squamous Cell Carcinoma

NCT01807546 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Anal Squamous Cell Carcinoma
Lung Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Skin Squamous Cell Carcinoma
Penile Squamous Cell Carcinoma

Interventions

DRUG: rigosertib

Sponsor

Traws Pharma, Inc.